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induced by a group of compounds influencing a common 
biological process. Applying DTNI on experimental data 
from TG-GATEs, we demonstrate that DTNI provides in-
depth information on the mode of action of compounds, 
in particular key events and potential molecular initiating 
events. Furthermore, DTNI also discloses several unknown 
interactions which have to be verified experimentally.
Keywords Time series · Dose–response · Gene regulatory 
network inference · Mode of action · Molecular initiating 
event · Key event
Introduction
A dedicated and robust analysis of human in vitro toxi-
cogenomics data by means of computational methods is 
crucial for the development of alternatives to animal test-
ing (Goh et al. 2015). In this context, studying the influ-
ence of toxic compounds on gene regulatory networks 
(GRN) is important for the identification of their adverse 
effects on the cellular level (Gautier et al. 2013). How-
ever, understanding how chemical compounds influence 
GRN is challenging, because it requires the identification 
of causal events (Liebler and Guengerich 2005). Thus, we 
need to reliably capture the dynamics of toxicogenomics 
responses. Time series analysis allows for detecting simi-
lar patterns across multiple time scales, while static data 
analysis through searching for associations only identifies 
simultaneously occurring patterns (Cavill et al. 2013; Hen-
drickx et al. 2015). Therefore, analyses of toxicogenomics 
responses over time are required to infer hypotheses on the 
order of causal events (Bar-Joseph et al. 2012). Apart from 
the time, the dose is also an important factor for identify-
ing mechanisms of toxicity (Allen et al. 2014). However, 
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time-over-dose integration approaches are currently 
lacking.
Open TG-GATEs (http://toxico.nibiohn.go.jp/) (Iga-
rashi et al. 2015), containing data from 158 hepatotoxic 
compounds generated from human primary hepatocytes 
at several time points and doses, provide the opportunity 
to explore time-over-dose integration methods in human 
in vitro data. However, previous analyses of the TG-GATEs 
data were mainly restricted to separate analyses per time 
point and dose (Chung et al. 2015; Grinberg et al. 2014; 
Kanki et al. 2016; Zhang et al. 2014). Chung et al. (2015) 
explored the probability of relationships between treatment, 
drug and time or dose. Grinberg et al. (2014) focussed 
on distinguishing stereotypic and compound-specific 
responses of gene expression by determining differentially 
expressed genes (DEGs). Kanki et al. (2016) applied multi-
variate analysis (principal component analysis) to study the 
mode of action of non-genotoxic hepatocarcinogens. Zhang 
et al. (2014) identified an early response network for cyto-
toxicity based on DEGs at the earliest time point (2 h) and 
prior knowledge on their interactions. However, these stud-
ies do not address the identification of novel gene interac-
tions and do not focus on time-over-dose integration.
Previously developed methods for inferring GRNs can 
be roughly divided into five types of approaches and com-
binations thereof: (1) linear regression; (2) pairwise scores; 
(3) nonlinear regression; (4) ordinary differential equations 
(ODE); and (5) Bayesian networks (Hill et al. 2016). How-
ever, none of these approaches takes into account that gene 
expression evolves with both time and dose.
Here, we have preferred to extend the ODE approach 
to GRN inference, because methods based on ODE are 
especially suitable for time series and aim at identifying 
quantitative dynamical gene regulatory interactions (Le 
Novere 2015). We present Dose-Time Network Identifica-
tion (DTNI), a novel method for GRN inference based on 
ODE and time-over-dose integration. DTNI extends exist-
ing ODE methods for GRN inference by including ODE 
describing the evolution of gene expression with the dose, 
while traditional ODE methods only describe the evolution 
of gene expression over time. We show that DTNI can be 
used to study a group of chemicals influencing a pathway 
or biological process of interest. Within this pathway or 
biological process, DTNI determines the subnetwork influ-
enced by this group of chemicals across all time points and 
doses. Analysis of subnetworks inferred by DTNI will elu-
cidate information about the molecular mechanisms under-
lying the adverse effects of toxic compounds.
First, we will study the performance of DTNI using sim-
ulated data on a pre-defined network, namely the IkB-NF-
kB signalling module. A simulation study aims at assessing 
how well a known network can be predicted by a network 
inference method, which cannot be accomplished by 
analysing experimental data, because for real data, biologi-
cal knowledge is uncertain and incomplete (Mendes et al. 
2005). Furthermore, simulations have the purpose to study 
how the performance of a network inference method would 
improve when sampling at a higher resolution that cannot 
be achieved with current experiments. This is important for 
future experimental design. Finally, simulations intend to 
determine the influence of a known level of noise (variation 
due to biological and/or technical factors), while for real 
data, only an estimation of the noise levels can be made.
Next, we will apply DTNI on experimental data on 
human hepatocytes from Open TG-GATEs in order to 
study two important pathways related to drug-induced liver 
injury (DILI): the nuclear factor-kappa B (NF-kB) signal-
ling pathway and the nuclear factor (erythroid-derived 
2)-like 2 (NRF2) pathway.
We furthermore demonstrate that heat maps of start-
ing nodes (nodes with only outgoing edges) in networks 
inferred with DTNI at the earliest time point can be used 
to infer potential molecular initiating events (MIEs) within 
the adverse outcome pathway (AOP) framework (Ankley 
et al. 2010).
Materials and methods
Time series network identification (TSNI)
TSNI (Bansal et al. 2006) is a network inference algorithm 
based on (linear) ODEs. The system of ODEs relates gene 
expression changes over time to each other and to a per-
turbation (in this study: exposure to a certain dose of a 
toxic compound). The method can include both constant 
and transient perturbations. Parameters in the ODEs are 
estimated by means of regression techniques and represent 
the interaction strengths between genes. In transcriptom-
ics data, the number of genes is mostly much larger than 
the number of measurements, and as a consequence, the 
ODEs do not have a unique solution. Therefore, the ODE 
approach is combined with an interpolation step to cal-
culate extra time points, and a dimension reduction step 
(comparable with principal component analysis). Param-
eters are first estimated in the reduced dimension space, 
and the obtained solution is then transformed to parameters 
for the original system of ODE. In this way, identifiabil-
ity problems are addressed and we obtain a unique set of 
parameters (interaction strengths) for the ODE.
TSNI has some shortcomings, which hamper applica-
tion of this method to toxicogenomics data. First, TSNI 
requires that data are sampled at equal time intervals, 
which is mostly not the case in toxicogenomics. Second, 
the response to a compound not only evolves over time, 
but also over dose. TSNI includes dependency of gene 
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expression time courses on the dose, but does not include 
ODEs that describe how gene expression evolves with 
dose given the time of exposure. Third, a threshold on the 
interaction strength determines which edges are kept in 
the network and which are not. These thresholds are quite 
arbitrary.
Hence, we developed a novel method, named DTNI that 
addresses these issues.
Dose‑Time Network Identification (DTNI)
DTNI extends TSNI by adding extra ODE describing the 
evolution of gene expression over dose, assuming depend-
ence on expression of the other genes and the time of expo-
sure. As in TSNI, a dimension reduction step is applied to 
avoid identifiability problems. Furthermore, the interpola-
tion step is adapted, in order to enable that a time series 
with equal sampling intervals is estimated in case of une-
qual sampling intervals. Moreover, an interpolation step for 
interpolating dose series is added, so that extra dose points 
can be estimated and unequal dose intervals can be han-
dled. Significance is calculated for each interaction by an 
adapted permutation test. Traditional permutation testing is 
not suitable for data obtained at multiple time points and 
multiple doses, because permutation testing assumes inde-
pendency between the measurements, and does not take 
into account time and dose dependencies. While the data 
depend on each other, this is not necessarily the case for 
the residuals of the ODE model (i.e. the difference between 
the real data and the data estimated from the ODE model). 
Therefore, we can permute the residuals instead of the data 
and add the permuted residuals to the data estimated from 
the ODE model (Lee and Braun 2012). We performed 1000 
permutations of the residuals and calculated a p value for 
each interaction, in the same way as for a traditional per-
mutation test. In this way, we could determine significance 
of the inferred interactions, instead of relying on arbi-
trary thresholds on the interaction strength. The method 
was implemented within MATLAB (MATLAB 2014). A 
detailed description of the algorithm is provided in Sup-
plementary Material 2. The MATLAB code is available in 
Supplementary Material 3.
Leave‑one‑out cross‑validation (LOOCV)
When determining the network affected by a group of com-
pounds, leave-one-out cross-validation (LOOCV) was per-
formed by leaving out the data from one compound. This 
was repeated for each compound in the data set to cre-
ate as many LOOCV data sets as there were compounds. 
DTNI was performed on each LOOCV data set. Interac-
tions found by applying DTNI to the full data set that were 
not found for all LOOCV data sets were removed from the 
network.
Performance of DTNI
To assess the performance of DTNI, a simulation study 
was conducted. Simulations were performed using the free 
software COPASI (http://copasi.org/), a bioinformatics tool 
able to simulate time series data from an ODE model by 
solving its equations over a time interval of interest (Hoops 
et al. 2006). A kinetic ODE model on the IkB-NF-kB sig-
nalling module (Hoffmann et al. 2002), which is part of the 
NF-kB pathway, was retrieved from the BioModels Data-
base (Li et al. 2010) (BioModels ID: BIOMD0000000140). 
The model is based on mass action kinetics, a detailed 
overview of all reactions, and ODE can be retrieved from 
the BioModels Database. Additional reactions for drugs 
acting on this pathway were added by adjusting the system 
of ODE as described in Sung and Simon (2004). The inter-
action network consists of 22 nodes and 92 edges. The list 
of drug reactions in the model and the interaction network 
is provided in Table S3-1 and Figure S3-1.
Data were simulated to compare the performance of 
DTNI with TSNI. Furthermore, the influence of the number 
of time points, number of doses, number of compounds, 
noise and LOOCV was assessed. Table S3-2 gives an over-
view of the simulations performed in this study.
Time series were simulated by solving the system of 
ODE with COPASI. Initial values of the variables in the 
model for all simulations are shown in Table S3-3. The 
doses of the compounds for each simulation are given in 
Table S3-4. An overview of the time points included in 
the simulated data is presented in Table S3-5. Control 
data were simulated by setting the concentration value 
of all compounds to zero. Log2 ratios were calculated as 
input voor TSNI and DTNI. For the simulations with three 
time points and three doses, the time points and the ratio 
between the doses were chosen in such a way that they 
reach the same values as in the TG-GATEs data, in order to 
mimic real experimental data as good as possible.
For the simulation study, we assess how well the net-
work of the IkB-NF-kB signalling module extracted from 
the BioModels Database can be identified by DTNI. There-
fore, we define (1) a direct gene–gene interaction: two 
genes interacting without the intervention of other genes; 
(2) an indirect gene–gene interaction: two genes interact-
ing through the intervention of one or more intermedi-
ate genes; (3) a true-positive interaction (TP): a correctly 
identified direct interaction; (4) a false-positive interaction 
(FP): an incorrectly identified direct interaction (the inter-
action in the network extracted from BioModels is indi-
rect, or there is no interaction); (5) a true negative (true 
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absent interaction) (TN): absence of a direct interaction is 
correctly identified; and (6) a false negative (false absent 
interaction) (FN): absence of a direct interaction is incor-
rectly identified (there is a direct interaction in the network 
extracted from BioModels).
The following performance measures were used to 
check out the inferred networks: (1) sensitivity (true-posi-
tive rate (TPR)): the proportion of directly interacting gene 
pairs that are inferred as such; (2) specificity (true-neg-
ative rate (TNR)): the proportion of not directly interact-
ing gene pairs that are inferred as such; (3) area under the 
receiver operator characteristics curve (AUROC): graph of 
TPR against the false-positive rate (FPR = 1 − TNR), a 
larger AUROC means a better prediction of the toxicant(s)-
induced GRN; (4) geometric mean score (geometric mean 
of the sensitivity and the specificity), a larger geometric 
mean score means a better prediction of the toxicant(s)-
induced GRN; and (5) positive predictive value (PPV): 
the proportion of direct interactions predicted by network 
inference that are true direct interactions.
Apart from conducting a simulation study, we also vali-
dated DTNI in real experiments with compounds that were 
known to have an effect on the peroxisome proliferator-
activated receptor (PPAR) signalling pathway, among other 
clofibrate. A detailed description of the experiments and 
their analysis is given in Supplementary Material 4 (para-
graph “Validation on real experiments—PPAR signalling 
pathway”).
Approach to analyse experimental data
The approach to analyse experimental data with DTNI is 
outlined in Fig. 1. Because experimental data consist of 
thousands of variables and only relatively few samples, the 
number of genes considered for further analysis had to be 
reduced. This was achieved by restricting the analysis to a 
group of genes involved in a pathway or biological process 
of particular interest. Compounds influencing this pathway 
were selected by determining DEGs (see below) for all 
compounds in the data set (in this study TG-GATEs) and 
analysing the lists of DEGs by means of over-representa-
tion analysis in ConsensusPathDB (CPDB) (http://consen-
suspathdb.org/) (Kamburov et al. 2013) to obtain a lists of 
pathways affected by the compounds. The data of the com-
pounds related to the pathway of interest are pooled and 
further analysed by applying DTNI (using only data of the 
genes involved in this pathway) to obtain a single network. 
Then, LOOCV was conducted by leaving out the data of 
one compound. The connections of the resulting interaction 
network were further validated by means of CPDB-induced 
network modules analysis and were classified using the fol-
lowing definitions: (1) a true-positive interaction (TP): a 
gene pair linked in CPDB by direct interaction or via bio-
logical variables not in the analysed gene list (pathway) that 
is predicted by DTNI as a directly interacting gene pair; (2) 
a false-positive interaction (FP): a gene pair only linked in 
CPDB via genes in the analysed gene list (pathway) that is 
predicted by DTNI as a directly interacting gene pair; and 
(3) a novel interaction: a gene pair not linked in CPDB that 
is predicted by DTNI as a directly interacting gene pair.
Subnetworks within the inferred networks were deter-
mined using NetworkAnalyzer/Subnetwork Creation in 
Cytoscape (version 3.2.1.) (Su et al. 2014). The function-
ality of the individual genes in the inferred networks was 
extracted from the GeneCards database (http://www.
genecards.org). GeneCards (Safran et al. 2010) provides 
Fig. 1  Overview of the 
approach to analyse experimen-
tal data with DTNI
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information on the function of genes from Genatlas (Frezal 
1998) and UniProtKB (The_UniProt_Consortium 2015). 
Over-representation analysis in CPDB was performed on 
the list of nodes of the inferred networks and their sub-
networks to obtain an overview of pathways related to the 
networks. The pathways in the list are related to effects on 
the cellular level involved in liver toxicity (e.g. apoptosis, 
inflammation). By analysing the function of the individual 
genes and the pathways extracted from CPDB, potential 
key events related to adverse outcomes of the group of 
compounds analysed can be detected. Furthermore, a heat 
map of the starting nodes (nodes with only outgoing edges) 
in the inferred network at the earliest time point (2 h) was 
created in order to infer potential MIEs.
Novel interactions not available from CPDB were fur-
ther analysed for putative functional relationships by con-
sulting the databases Biograph, STRING and CTD. We 
inferred putative functional relationships from known 
interactions (genetic interactions, protein interactions, bio-
chemical reactions) by automated hypothesis generation in 
Biograph (http://biograph.be/) (Liekens et al. 2011), a data-
base integrating 21 publicly available sources containing 
biomedical relations. Furthermore, we identified functional 
relationships between genes in STRING (http://string-db.
org/) (Jensen et al. 2009), a database integrating experi-
mental repositories, computationally predicted interactions 
and text mining. Finally, interactions of the gene pairs with 
the studied compounds were retrieved from the Compara-
tive Toxicogenomics Database (CTD) (http://ctdbase.org/) 
(Davis et al. 2015). When a gene regulatory relationship 
was found in Biograph, we further investigated whether 
the genes have a common gene function using GeneCards 
database.
To determine whether the resulting network was specific 
for compounds affecting the studied pathway, the DTNI 
analysis was repeated for an arbitrary group of compounds 
in TG-GATEs not affecting this pathway.
TG‑GATEs data
Microarray data were retrieved from TG-GATEs (http://
toxico.nibiohn.go.jp/) (Igarashi et al. 2015). This database 
comprises, among other measurements, a large in vitro data 
set from human hepatocytes exposed to 158 chemicals of 
pharmaceutical interest, of which many are known to cause 
DILI (Chen et al. 2011, 2013). Data were measured for two 
biological replicates at up to three doses (low, middle and 
high, with a ratio 1:5:25) across three time points (2, 8 and 
24 h) and include also time-matched controls. The high-
est dose is the level corresponding to a 80–90% survival 
ratio, except for chemicals poorly dissolving in the vehicle, 
where the highest dose is the maximum solubility of the 
chemical (Igarashi et al. 2015).
Pre‑processing and normalization
Prior to analysis, compounds were pre-selected based on 
full availability of data from doses, time points and both 
replicates. Raw files were then pre-processed using the R 
package affy (Gautier et al. 2004), in which quality con-
trol, background correction and robust multiarray averag-
ing normalization (RMA) were performed separately for 
all chemical sets (containing 24 arrays each). Probe rean-
notation was performed using a customCDF annotation 
(version 19) with Entrez gene identifiers for Affymetrix 




The R/Bioconductor package LIMMA (Ritchie et al. 2015) 
was used to perform a moderated t-test for each chemical 
set independently to compare mean intensities across all 
doses to those from time-matched controls. For the two 
biological replicates in the data set, treatments were paired 
to controls. DEGs were further selected by applying the 
following criteria: (1) absolute fold change of 1.5 and (2) 
adjusted p value (Benjamini–Hochberg) ≤0.05.
Pathway analysis
From the pathway lists obtained by means of over-repre-
sentation analysis in ConsensusPathDB, pathways with 
adjusted p value (q value) lower than 0.05 were considered 
significant.
Selection of pathways
We selected the NF-kB and the NRF2 pathways as exam-
ples to evaluate DTNI, because these pathways are very 
well established in the literature, in comparison with other 
DILI-related pathways.
Example 1: NF‑kB pathway
The data of the compounds influencing the NF-kB path-
way were analysed by applying DTNI. The NF-kB path-
way was selected a priori because it is known to play an 
important role in toxicant-induced liver injury (He and 
Karin 2011). Activation of this pathway has been related to 
hepatic inflammation, fibrosis, development of hepatocel-
lular carcinoma, cholestasis, cirrhosis, apoptosis, necrosis 
and hepatic steatosis (Elsharkawy and Mann 2007; He and 
Karin 2011).
The NF-kB pathway was extracted from KEGG 
(http://www.genome.jp/kegg/) (Kanehisa et al. 2016) 
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and consisted of 91 genes, of which 87 were present in 
TG-GATEs.
Example 2: NRF2 pathway
We analysed the data of the compounds influencing the 
NRF2 pathway. The NRF2 pathway is one of the main 
pathways protecting the liver from DILI, in particular 
caused by oxidative and electrophilic stress (Klaassen and 
Reisman 2010). Activation of NRF2 prevents liver inflam-
mation, necrosis, cholestasis and fibrosis (Bataille and 
Manautou 2012; Klaassen and Reisman 2010; Tang et al. 
2014).
The NRF2 pathway was extracted from Wikipathways 
(http://www.wikipathways.org) (Kutmon et al. 2016) 




Figure S3-2 compares DTNI with TSNI for simulated data 
of a single compound with three time points (2, 8, 24 h), 
three doses (low, middle and high) and time-matched con-
trols (dose = 0). ROC curves were produced by varying the 
p value threshold and calculating true-positive rates and 
false-positive rates. The resulting ROC curves show that 
DTNI outperforms TSNI in predicting a toxicant-induced 
network (AUROC for DTNI ~5% larger than for TSNI).
Figures S3-3a and S3-3b show that increasing the num-
ber of time points or the number of doses leads to a better 
prediction of a toxicant-induced network (increase in geo-
metric mean score in Figures S3-3a and S3-3b, demonstrat-
ing better sensitivity/specificity). However, the curves of 
Figures S3-3a and S3-3b only slightly increase after hav-
ing 72 time points and 14 doses, respectively. Figure S3-3c 
shows that the prediction of a toxicant-induced network 
increases with the number of compounds (increase in geo-
metric mean score in Figure S3-3c).
The ROC curves in Figure S3-3d show that noise (varia-
tion due to biological and/or technical factors) significantly 
influences the performance of DTNI. However, as to be 
expected, having replicates reduces the influence of noise.
Figure S3-4 shows that applying LOOCV significantly 
increases the proportion of direct interactions predicted by 
DTNI that are true direct interactions (increased PPV in 
Figure S3-4).
For the real experiments of compounds affecting the 
PPAR signalling pathway, geometric mean scores of ~0.69 
(69%) were obtained (see Table S3-6). Furthermore, the 
inferred network for clofibrate contains key genes for 
compound reactions, but also many other genes, of which 
most of them have already been related to clofibrate expo-
sure in previous studies (see Table S3-7).
TG‑GATEs data
Example 1: NF‑kB pathway
Four compounds could be related to the NF-kB pathway 
upon over-representation analysis of the DEGs: acetami-
nophen, carbon tetrachloride, interleukin-1 and interleu-
kin-6. The interaction network inferred by applying DTNI 
on this group of compounds consists of 25 nodes, con-
nected by 21 edges (Figure S4-1), of which 14 connections 
(66.7%) are true-positive interactions, only 2 connections 
are false-positive interactions (9.5%) and 5 connections are 
unknown (23.8%). Details on the edges are presented in 
Table S4-1. Table S4-2 presents the list of pathways related 
to the inferred network. The network can be divided into 
6 subnetworks (Figure S4-1 and Table S4-3). The inferred 
network and its subnetworks are related to apoptotic path-
ways (a.o. TNF and FAS signalling) and inflammatory 
response pathways (cytokine signalling, a.o. interleukin 
and TNF signalling; TLR signalling).
Within the complete network of 25 nodes, 12 were 
starting nodes (with only outgoing edges). Figure S4-2 
presents a heat map of these starting nodes at the earliest 
time point (2 h). TLR4, which plays a role in the inflam-
matory response (Broering et al. 2011), seems to be the 
most affected by 3 out of 4 compounds at the earliest time 
point. Furthermore, the other genes in the inferred network 
are involved in DNA recombination, cell cycle progression, 
apoptosis, the inflammatory response, signal transduction, 
cell–cell recognition, cell adhesion, immune response, 
DNA repair, cell growth, differentiation and tumorigenesis 
(Table S4-4).
When further analysing the five unknown interactions, 
for three of the five gene pairs, a putative relationship 
could be inferred from Biograph (Table S4-5): CFLAR-
LTB, PLCG2-ICAM1 and TNFRSF11A-CD14. These gene 
pairs could be connected through intermediates involved 
in inflammatory response, cell–cell communication and 
immune response, respectively. The interaction involved 
in cell–cell communication could also be predicted from 
STRING (Table S4-6). One of the five gene pairs (LBP-
TNFSF14) could only be connected in CTD by its interac-
tion with acetaminophen (Tables S4-7 and S4-8). For the 
remaining unknown gene interaction (LTB → ICAM1), no 
evidence for a functional relationship could be found in the 
consulted databases.
When DTNI analysis was repeated for 4 compounds not 
affecting the NF-kB pathway (in our case diazepam, indo-
methacin, omeprazole and hepatocyte growth factor), none 
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of the 21 edges in Figure S4-1 could be inferred, which 
shows that the network in Figure S4-1 is specific for com-
pounds affecting the NF-kB pathway.
Example 2: NRF2 pathway
By performing pathway analysis on the DEGs, we found 
ten compounds related to the NRF2 pathway: azathio-
prine, carbamazepine, coumarin, diazepam, flutamide, 
ketoconazole, lomustine, nitrofurantoin, propylthiouracil 
and valproic acid. DTNI, applied to this group of com-
pounds, inferred an interaction network of 123 nodes, con-
nected by 811 edges (Figure S5-1). Within the network, 
196 connections (24.0%) are true-positive interactions, 
23 are false-positive interactions (3.0%), and 592 connec-
tions are unknown (73.0%). Table S5-1 presents the details 
on the edges. The network has no subnetworks. Pathways 
related to the inferred network are listed in Table S5-2. The 
inferred network is related to solute carrier (SLC)-medi-
ated transmembrane transport, biotransformation pathways 
(phase I/phase II), response to oxidative stress (e.g. degra-
dation of reactive oxygen species), metabolism (carbohy-
drates, amino acids, nucleotides), aryl hydrocarbon recep-
tor signalling, apoptosis, tumour protein p53 signalling, 
transforming growth factor beta signalling, gene regula-
tion by peroxisome proliferators and ABC family proteins-
mediated transport.
Within the complete network of 123 nodes, 13 were 
starting nodes. The heat map in Figure S5-2 shows that 
SLC5A9 is most affected at the earliest time point (2 h). 
SLC5A9 plays a role in transporter activity and metabo-
lism, in particular the carbohydrate metabolism (Tazawa 
et al. 2005). The other genes in the inferred network are 
involved in metabolism, drug resistance, transporter activ-
ity, immune system, cell–cell communication, apoptosis, 
development, cell growth, tissue repair, tumorigenesis, cel-
lular senescence, protection against oxidative stress, drug 
metabolism, protein folding and degradation, inflammatory 
response, redox regulation of the cell, survival, chemotaxis, 
circadian entrainment, detoxification and elimination of 
xenobiotics, cellular stress response, autophagy, cytoskel-
etal organization (Table S5-3).
For 63 of the 592 unknown interactions, a putative rela-
tionship could be inferred in BioGraph (Table S5-4). When 
restricting to the ten interactions in Biograph that have the 
highest interaction strength (determined by DTNI), we 
found that five gene pairs could only be related to each 
other because both genes react with NADP, water or oxy-
gen (Table S5-5). Interaction between the other five gene 
pairs (SLC6A9-HSPA1A, MAFG-SLC39A7, SLC6A8-
HSPA1A, TXN-HBEGF and PDGFB-NRG1) could be 
explained by a common biological function between the 
genes (Table S5-5). SLC6A9-HSPA1A could be connected 
by intermediates involved in inflammatory response. 
MAFG-SLC39A7, SLC6A8-HSPA1A and their intermedi-
ates play a role in cell signalling. The interaction of TXN 
and HBEGF through EGFR is part of the immune system. 
PDGFB-NRG1 and its intermediates play a role in cell–cell 
communication.
Thirteen interactions could be retrieved from STRING, 
of which 4 could also be inferred from Biograph (Table 
S5-8). One interaction was known from curated databases, 
two were experimentally determined, one gene pair was 
known to be co-expressed, and the remainder could be 
extracted with the help of text mining (Table S5-6). A total 
of 379 gene pairs could only be connected in CTD by their 
interaction with at least one of the 10 studied compounds 
(Tables S5-7 and S5-8). For the remaining 141 interactions, 
no evidence for a functional relationship could be found in 
the consulted databases.
When DTNI analysis was repeated for 10 compounds 
not affecting the NRF2 pathway (in our case indomethacin, 
omeprazole, hepatic growth factor, diclofenac, haloperidol, 
adapin, allopurinol, benzbromarone, ethionine and fluphen-
azine), 32 (3.9%) of the 811 edges in Figure S5-1 could be 
inferred, which shows that 96.1% of the network in Figure 
S5-1 is specific for compounds affecting the NRF2 path-
way. Of the 32 edges in the overlap, 9 were true-positive 
interactions and 23 unknown in CPDB. The 9 true-posi-
tive interactions are relationships between genes from the 
NRF2 pathway that occur in other pathways, in particular 
xenobiotics metabolism by cytochrome P450 and transport 
pathways (Table S5-9). Of the 23 unknown interactions, 
none of the gene pairs has overlap in GO terms or an inter-
action in STRING. Only 4 of these 23 interactions could 
be inferred from known interactions in Biograph (Table 
S5-10). Three of the 32 interactions in the intersection have 
gene pairs that are affected by one of the 10 compounds 
(not affecting the NRF2 pathway) in CTD: TGFA-GCLC 
(both affected by diclofenac), TXN-HBEGF (both affected 
by diclofenac) and SLC7A11-ABCC3 (both affected by 
indomethacin).
Discussion
Unravelling the mechanism of action (MoA) of compounds 
is a challenging topic in toxicology. Previous methods for 
elucidating MoA by analysing gene expression data on 
multiple time points and doses, such as DeMAND (Woo 
et al. 2015), require a pathway with its genes and inter-
actions as input and test the dysregulation of the known 
interactions of each gene within this pathway, in order 
to provide a list of genes that are most dysregulated by 
the toxicant. In contrast to methods such as DeMAND, 
DTNI only requires a gene list of a pathway (or biological 
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process) of interest as input and not its interactions. There-
fore, DTNI not only tests (dys)regulation of existing inter-
actions, but also infers novel interactions that can be tested 
experimentally. Furthermore, the output of DTNI is a list of 
interactions with their statistical significance, while meth-
ods such as DeMAND provide a list of genes with their 
statistical significance. As a consequence, DTNI provides 
information complementary to the output of DeMAND.
An interaction in a network inferred with DTNI can 
occur due to several reasons: (1) a direct gene–gene inter-
action; (2) an indirect gene–gene interaction (through one 
or more intermediates); (3) both genes affected by one or 
more of the studied compounds.
The ROC curves for the simulations show that DTNI 
outperforms TSNI in inferring a network induced by a toxi-
cant. Moreover, DTNI allows including data from multiple 
perturbations (compounds), while only one perturbation 
can be included within TSNI. Including multiple com-
pounds has the additional advantage that a LOOCV step 
can be applied, leaving out one compound, which further 
improves the proportion of direct interactions predicted by 
network inference that are true direct interactions (PPV).
In this study, we demonstrated the performance of DTNI 
on experimental data for two groups of compounds: those 
affecting the NF-kB pathway and those influencing the 
NRF2 pathway.
The network inferred for the NF-kB pathway is spe-
cific for compounds affecting this pathway and cannot be 
inferred when analysing a group of compounds not influenc-
ing the NF-kB pathway. For the NRF2 pathway, most of the 
network (96.1%) was specific for compounds affecting that 
pathway. This shows that DTNI can infer a network specific 
for compounds affecting a common pathway for a moderate 
number (≤90) genes, but also that the performance in terms 
of inferring a network specific for a group of compounds 
slightly decreases when evaluating larger networks.
In the first example, the NF-kB pathway, we found a net-
work related to apoptosis and inflammation, which are key 
events in both the AOPs for drug-induced liver fibrosis and 
cholestasis (Vinken 2015). From the starting nodes already 
induced after 2 h of drug treatment, TLR4 was the most 
affected (inhibition, Figure S4-2). TLR4 has an impor-
tant role in pathogen recognition and activates the innate 
immune system (Broering et al. 2011). Also, down-regula-
tion of TLR4 has been related to liver cirrhosis (Manigold 
et al. 2003). This suggests that down-regulation of TLR4 is 
a potential MIE in these AOPs. From the four compounds 
affecting the NF-kB pathway, two compounds (acetami-
nophen and carbon tetrachloride) have been reported to 
affect the expression of TLR4 (Beyer et al. 2007; De Mini-
cis et al. 2007). Furthermore, it has been shown that TLR4 
activity increases susceptibility to acetaminophen (Yohe 
et al. 2006).
The network inferred for the NRF2 pathway is involved 
in pathways which are associated with key events indi-
cated in AOPs for fibrosis (TGFB signalling, apoptosis) 
or cholestasis (oxidative stress, apoptosis) (Vinken 2015), 
or are related to liver cancer (p53 signalling (Hanahan and 
Weinberg 2011), SLC-mediated transmembrane trans-
port (El-Gebali et al. 2013)). SLC5A9 (inhibition, Figure 
S5-2) was the most affected starting node at 2 h of treat-
ment, which suggests that down-regulation of SLC5A9 is 
a potential MIE in an AOP for fibrosis, cholestasis or liver 
cancer. SLCA9 regulates sodium-dependent glucose trans-
port (Tazawa et al. 2005). To our knowledge, a relationship 
between SLC5A9 and fibrosis, cholestasis or liver cancer 
has not yet been established, so this presents a novel find-
ing which has to be verified experimentally. However, a 
relationship between SLCs in general and cancer has been 
reported (El-Gebali et al. 2013). The ten compounds influ-
encing the NFR2 pathway were also not known to induce 
SLC5A9.
For the NF-kB pathway, the largest percentage of edges 
in the network (66.7%) is true-positive interactions, while 
only 9.5% of the edges were false-positive interactions. 
This shows that DTNI is a reliable method for analysing 
a group of genes of moderate size (≤90 genes). Further-
more, 23.8% of unknown interactions could be discovered. 
Three of the five unknown interactions in CPDB could be 
predicted from known relationships in Biograph and/or 
STRING. One interaction could only be explained by the 
influence of one of the studied compounds on both genes. 
For the remaining interaction, no evidence could be found 
in the consulted databases.
For the larger group of genes of the NRF2 pathway, the 
percentage of true-positive interactions was still high (24%) 
compared to the number of false-positive interactions (3%). 
Interestingly, the largest part of the network (73%) repre-
sents unknown interactions. It has to be noted that on the 
Wikipathways website, it is reported that the NRF2 path-
way is not fully connected and probably incomplete (http://
www.wikipathways.org/index.php/Pathway:WP2884). This 
could explain the large percentage of unknown interactions 
reported here. After further consulting of other biological 
databases (Biograph, STRING, CTD), 72 of these interac-
tions could be explained from known interactions in Bio-
graph and/or STRING. For 379 interactions, the only evi-
dence for an interaction was that at least one of the studied 
compounds affected both genes. For the remaining 141 
interactions, no evidence could be extracted.
In summary, these two examples show that DTNI anal-
ysis is a suitable method for causally inferring key events 
and potential MIEs in AOPs across dose and time when the 
number of genes analysed is of moderate size. DTNI also 
detects novel interactions which have to be verified experi-
mentally, e.g. by gene knockdown experiments.
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